Aucubin

Other Names

(1S,4aR,5S,7aS)-1,4a,5,7a-Tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl β-D-glucopyranoside(1S,4aR,5S,7aS)-5-Hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl β-D-glucopyranoside(1S-(1alpha,4aalpha,5alpha,7aalpha))-1,4a,5,7a-Tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-beta-D-glucopyranoside(2S,3R,4S,5S,6R)-2-((1S,4aR,5R,7aS)-5-Hydroxy-7-hydroxymethyl-1,4a,5,7a-tetrahydro-cyclopenta[c]pyran-1-yloxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol(2S,3R,4S,5S,6R)-2-[[(1S,4aR,5S,7aS)-5-Hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-1-yl]oxy]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol(2S,3R,4S,5S,6R)-2-{[(1S,4aR,5S,7aS)-5-hydroxy-7-(hydroxymethyl)-1H,4aH,5H,7aH-cyclopenta[c]pyran-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triolAIDS-031379AucubineAucubosidAucubosideiridoid glucoside aucubiniridoid glycoside aucubinNSC407293Rhinanthinβ-D-glucopyranoside, (1S,4aR,5S,7aS)-1,4a,5,7a-tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta[c]pyran-1-yl

Synopsis

Aucubin: A Comprehensive Reference

1. Identity: Chemical and Botanical Profile

1.1 Nomenclature and Chemical Identity

Aucubin, whose full IUPAC-based systematic name is (1S-(1alpha,4aalpha,5alpha,7aalpha))-1,4a,5,7a-Tetrahydro-5-hydroxy-7-(hydroxymethyl)cyclopenta(c)pyran-1-yl-beta-D-glucopyranoside, is an iridoid glycoside. It is also encountered in the literature under the abbreviation "AU." The compound is alternatively described chemically as 1,4a,5,7a-Tetrahydro-5-hydroxy-7-hydroxymethylcyclopenta(c)pyran-1-yl-beta-D-glucopyranoside and belongs to the class of iridoid glycosides present in natural medicine.

Iridoids belong to the terpenoid group and contain a six-membered ring structure with oxygen atoms fused to a cyclopentane ring, and in nature they commonly exist in the form of a glycoside. Based on etymology, the term "iridoid" means that it is obtained from the volatile monoterpenes iridodial and iridomyrmecin, which compose the defensive secretion of Australian ants from the genus Iridomyrmex; according to its biosynthetic origin, the classical name iridoid refers to natural monoterpenoids — secondary plant metabolites characterized by a cyclopenta[c]pyranoid skeleton, also called iridane.

Aucubin has a molecular weight of 346.33 g/mol, a melting point of 181 °C, a water solubility of 3.56 × 10⁻⁵ mg/L at 20 °C, and a logP value of −3.49. Polar iridoid glycosides such as aucubin dissolve well in water and alcohols (methanol, ethanol, n-butanol). Aucubin is unstable and can be deglycosylated into its aglycone, aucubigenin.

1.2 Botanical Sources

Aucubin is an iridoid glycoside widely spread in the families Cornaceae, Garryaceae, Orobanchaceae, Globulariaceae, Eucommiaceae, Scrophulariaceae, Plantaginaceae, and Rubiaceae. It is a type of iridoid found in several plant families, particularly Scrophulariaceae, Plantaginaceae, and Rubiaceae, serving as their chemotaxonomic marker.

Among the most investigated and commercially significant source plants are:

Eucommia ulmoides Oliv. (Eucommiaceae): Indigenous to China and growing to 15–20 m in height, Eucommia ulmoides is widely distributed in Shanxi, Gansu, Zhejiang, Henan, Hubei, Sichuan, Guizhou, and Yunnan. Chlorogenic acid and certain iridoids — aucubin, geniposidic acid, and geniposide — have been demonstrated to be the main and active ingredients in this plant.
Aucuba japonica Thunb. (Garryaceae/Cornaceae): Since the first discovery of aucubin in Aucuba japonica in 1905, scientists have reported that it exists in many natural plants such as Eucommia ulmoides Oliv., Aucuba japonica Thunb., and Plantago asiatica L.
Plantago species (Plantaginaceae): The major iridoid glycoside found in Plantago major is aucubin, but its content varies over the seasons; the highest aucubin level registered (1.3% in dried leaves) was in June. P. major contains less aucubin than P. lanceolata.
Rehmannia glutinosa Gaertn. (Orobanchaceae): The main active ingredient of traditional Chinese medicines Eucommia ulmoides, Rehmannia glutinosa, and plantain is the iridoid glucoside aucubin.

Aucubin is generally present in plants' leaves, fruits, and stems, but its presence in root tissue has also been reported. To date, AU has only been extracted from plants; because of the unstable structure of AU, few pure products can be obtained.

1.3 Common Forms and Preparations

For clinical and pharmaceutical practice, plants containing aucubin can be used in the form of crude drugs, extracts, extract fractions, and isolates. Various chromatographic methods — column chromatography, vacuum liquid chromatography, medium pressure liquid chromatography, and high-performance liquid chromatography — have been used together to isolate aucubin, mainly with the stationary phase C-18 and the mobile phase water–methanol solution made in gradients.

Various isolation methods have been tested and developed because pure aucubin plays an essential role in standardizing raw materials and traditional medicinal products, synthesizing other iridoid glycosides, product development, and pharmacological, pharmacodynamic, and pharmacokinetic studies. In research settings, aucubin is administered in isolated, purified form, while traditional and functional food applications typically employ the whole plant or standardized plant extracts. The bark, leaves, and fruit of source plants are all utilized depending on the tradition.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

Eucommia ulmoides (EUO), a traditional Chinese herb, is one of the representative medicines for "tonifying the kidney," with a long history of use of more than 2,000 years. Bioactive chemicals of EUO include lignans, iridoids, phenols, and steroids, which play effective roles in processes such as nourishing the kidneys, neuroprotection, and regulating blood pressure.

Eucommia ulmoides has been used for the treatment of various diseases since ancient times, involving lumbar pain, knee pain, osteoporosis, hepatoprotection, paralysis, intestinal haemorrhoids, vaginal bleeding, abortion, and spermatorrhoea. Traditional Chinese medicine Cortex Eucommiae (the bark of E. ulmoides) has been used to treat bone fracture for hundreds of years, and it exerts a significant improvement in fracture healing.

Aucubin is also a key constituent in Rehmannia glutinosa, known in TCM as "Dihuang." The iridoid glycosides including aucubin, catalpol, swertimarin, and gardenoside are frequently found as natural constituents of many traditional oriental medicinal plants including Chinese herbs. These herbs were and are employed in decoctions (water extractions), prepared by prolonged boiling of dried plant material, as well as in prepared pill formulas in classical TCM practice. Traditional Chinese medicines have been used for more than 2,000 years and have gained widespread clinical application over this period.

2.2 Plantago (Plantain) Traditions

Plantago species contain aucubin and catalpol iridoid glycosides that have been used in traditional medicine for many purposes. Plantago major (greater plantain) and P. lanceolata (ribwort plantain) have long histories of use in European, Asian, and indigenous American herbal traditions. Aerial parts — leaves in particular — were prepared as fresh-plant poultices, water infusions (teas), and tinctures for topical wound care, respiratory complaints, and urinary conditions. The wide global distribution of Plantago species contributed to their independent adoption across multiple herbal systems.

2.3 Ayurvedic and Other Asian Traditions

Eucommia ulmoides, the sole species of the genus Eucommia, has been traditionally used in various indigenous systems of medicines, and in vitro and in vivo pharmacological studies have increasingly confirmed its traditional use, especially on joint diseases and kidney asthenia. AU (aucubin) provides moist heat, analgesic, antihypertensive, liver protection, and antitumor effects according to traditional Chinese medical texts.

3. Key Constituents and Mechanisms of Action

3.1 Primary Active Compound and Metabolite

Aucubin itself is the primary bioactive constituent of interest. Upon enzymatic or acid hydrolysis, the glycosidic bond is cleaved to yield the aglycone aucubigenin. Aucubin is a glycoside whose aglycone (aucubigenin) binds to the glucose group using an O-glycosidic bond. Aucubigenin is believed to contribute additional pharmacological activity, and studies on aucubin and aucubigenin pharmacology have been summarized together in several Chinese-language reviews.

3.2 Anti-inflammatory Mechanisms

The best-characterized mechanism of aucubin is suppression of the NF-κB inflammatory signaling cascade. Aucubin has been shown to inhibit TLR4/NF-κB signaling in hepatocytes and thereby downregulate inflammatory TNF-α and IL-1β.

In chondrocyte models, aucubin significantly reversed the elevated gene and protein expression of MMP-3, MMP-9, MMP-13, iNOS, COX-2, and the production of NO induced by IL-1β challenge in rat chondrocytes; furthermore, aucubin suppressed the IL-1β-mediated phosphorylation and nuclear translocation of p65, indicating it may act via the NF-κB signaling pathway.

In liver tissue, measurement of TLR-4, myeloid differentiation factor 88 (MyD88), NF-κB P65, p-P65, IκB-α, and p-IκB-α levels showed that aucubin effectively inhibited activation of the TLR-4/NF-κB signaling pathway.

In neurological contexts, ischemia–reperfusion (IR)-induced increases in IL-1β and TNF-α levels were significantly alleviated by aucubin treatment; IR-induced upregulation of TLR4 and downregulation of IκBα were significantly prevented, and IR-induced nuclear translocation of NF-κB was reversed by aucubin treatment.

In the context of macrophage polarization, aucubin's ability to mitigate pathological osteonecrosis involves suppression of TLR4/NF-κB signaling and promotion of macrophage polarization to an anti-inflammatory M2 phenotype.

3.3 Antioxidant Mechanisms

Aucubin activates NF-E2-related factor 2 (Nrf2), peroxisome proliferator-activated receptor α (PPARα), PPARγ, and heme oxygenase-1 (HO-1), and promotes the phosphorylation of AMP-activated protein kinase (AMPKα), AMPKβ, acetyl-CoA carboxylase (ACC), and protein kinase B (AKT).

In bone tissue, aucubin enhanced the expression of anti-oxidative stress-associated factors in the Nrf2 signaling pathway, including superoxide dismutases 1 and 2, heme oxygenases 1 and 2, and catalase in dexamethasone-treated and H₂O₂-treated osteoblast-like cells.

3.4 Anti-apoptotic and Cytoprotective Mechanisms

In mice with OA induced by meniscal ligament transection, aucubin inhibited the expression of pro-apoptotic factors (BAX, caspase-9, and caspase-3), increased BCL-2 expression, and reduced ROS production.

In neurons, aucubin reduced the number of dead neurons, increased the number of surviving neurons, inhibited necroptosis proteins (MLKL, RIP-1), enhanced autophagy proteins (Beclin-1 and LC3BII/LC3BI), reduced levels of IL-1β, HMGB1, and TNF-α, and increased levels of GABA while decreasing glutamate in the hippocampus.

3.5 Bone Metabolic Mechanisms

Aucubin and geniposidic acid (iridoids found in Eucommia ulmoides) have been shown to stimulate osteoblastic bone formation and inhibit osteoclastic bone resorption. Aucubin consistently promotes osteoblastogenesis and inhibits osteoclastogenesis through modulation of key signaling pathways, including BMP/SMAD, Wnt/β-catenin, OPG/RANKL, and MAPK/NF-κB.

4. Scientific Evidence by Area of Use

Important context for all subsections below: Even though aucubin has been extensively investigated, further research in humans is urgently needed primarily to substantiate the clinical evidence. Clinical studies are needed to confirm the efficacy of aucubin in specific diseases. Most pharmacological activities have been measured using complex extracts or single isolated compounds in vitro or in vivo with cells or animals; some data from animal studies were obtained using exorbitant doses, and no relevant components were detected in blood in some cases. As of this writing, there are no published randomized controlled clinical trials using isolated aucubin as the sole intervention in humans. Evidence across all areas below is therefore classified as preclinical unless otherwise specified.

4.1 Anti-inflammatory Activity

Evidence level: Preclinical (in vitro and in vivo animal studies).

The anti-inflammatory properties of aucubin have been documented across a wide range of experimental models. When applied topically, aucubin has an inhibitory effect on TPA (12-O-tetradecanoylphorbol acetate)-induced mouse ear edema, with a maximum effect at a dose of 1 mg/ear; this effect is close to that of indomethacin at 0.5 mg/ear. In rat chondrocytes, studies were aimed at investigating the effects of aucubin on IL-1β-stimulated rat chondrocytes, which were pretreated with aucubin at 1, 10, 20, or 50 μM. These in vitro experiments established that aucubin modulates NF-κB-dependent inflammatory gene expression and matrix metalloproteinase production relevant to osteoarthritis. The studies proposed that aucubin may be a potential therapeutic choice in the treatment of OA due to its anti-inflammatory and chondroprotective features.

4.2 Hepatoprotection (Liver Protection)

Evidence level: Preclinical (animal and cell-based studies). Traditional evidence is longstanding. No human clinical trials identified for isolated aucubin.

Aucubin (AU) was systematically studied for its potent liver-protective activities using experimental systems of hepatic damage; AU showed high liver-protective activity against carbon tetrachloride-induced hepatic damage in mice, and also showed significant protective activity against alpha-amanitin-induced hepatic damage in mice, preventing a depression of liver RNA biosynthesis caused by alpha-amanitin administration.

In a rat liver ischemia-reperfusion (IRI) model, Sprague–Dawley rats were randomly divided into five groups; the AU low-dose (AU-L), AU medium-dose (AU-M), and AU high-dose (AU-H) groups were given intraperitoneal injections of AU at doses of 1, 5, and 10 mg/kg/day, respectively. The results showed that AU effectively inhibited activation of the TLR-4/NF-κB signaling pathway; it was concluded that aucubin exerted hepatoprotective effects in liver IRI by inhibiting the HMGB1/TLR-4/NF-κB signaling pathway, oxidative stress, and apoptosis, and that pretreatment with AU may be a promising strategy for preventing liver IRI.

In a NAFLD model, AU activated Nrf2, PPARα, PPARγ, and HO-1, and promoted the phosphorylation of AMPK and AKT; it was concluded that AU performed hypolipidemic functions via anti-inflammation and antioxidant activity, which may make it a kind of new drug targeting NAFLD.

Regarding liver fibrosis in a diabetic model, results showed that AU restored hepatic function without affecting blood sugar levels in diabetic mice, and the enhanced levels of total cholesterol, triglycerides, and LDL-c were reversed in hepatic tissue after AU treatment.

A network pharmacology and molecular simulation study explored potential targets and signal pathways of AU in inhibiting acute hepatitis, concluding that AU exerted anti-inflammatory and antioxidant activities and may be a useful candidate drug for the treatment of acute hepatitis. This study used computational methods (network pharmacology), not clinical patients.

4.3 Neuroprotection and Neurological Disease

Evidence level: Preclinical (animal models and cell-culture studies). No human RCTs identified.

Studies reviewed in a 2022 systematic review of aucubin in neurological diseases reported that AU improved the symptoms or prognosis of Parkinson's disease, Alzheimer's disease, intracerebral hemorrhage, diabetic encephalopathy, epilepsy, anxiety and depression, and traumatic brain injury — all in preclinical settings.

In a gerbil model of cerebral ischemia-reperfusion injury, the study evaluated whether aucubin exhibited neuroprotective effects against IR injury in the hippocampal CA1 region through anti-inflammatory activity; aucubin (10 mg/kg) was administered intraperitoneally once a day for one week prior to IR. Aucubin treatment protected pyramidal neurons from IR injury, and IR-induced microgliosis and astrogliosis were suppressed by aucubin treatment.

Regarding epilepsy, aucubin inhibits seizures induced by pilocarpine associated with lithium chloride; in this context, aucubin reduced the number of dead neurons, increased the number of surviving neurons, inhibited necroptosis proteins (MLKL, RIP-1), enhanced autophagy proteins (Beclin-1 and LC3BII/LC3BI), reduced levels of IL-1β, HMGB1, and TNF-α, increased GABA, and decreased glutamate in the hippocampus.

Studies have shown that aucubin improves the symptoms or prognosis of Parkinson's disease, Alzheimer's disease, intracerebral hemorrhage, diabetic encephalopathy, epilepsy, anxiety and depression, and traumatic brain injury. These findings derive from animal and cell-culture models; translation to human outcomes has not been established.

4.4 Bone and Joint Health (Osteoprotection)

Evidence level: Preclinical (cell and animal studies, including one study using human-derived cells). No completed human clinical trials identified for isolated aucubin.

Studies have found that aucubin is related to bone metabolism by increasing bone formation. Aucubin, an iridoid glycoside primarily derived from Eucommia ulmoides, is reported to inhibit osteoclast activity, enhance bone formation, and promote angiogenesis in osteoporosis models.

In a dexamethasone (Dex)-induced mouse model of osteoporosis, investigators examined the effects of AU on MG63 human osteoblast-like cells treated with dexamethasone or hydrogen peroxide to induce oxidative damage; AU protected cells against apoptosis and promoted increased expression of cytokines associated with osteoblast differentiation, including collagen I, osteocalcin, osteopontin, and osterix. In vivo, using a Dex-induced mouse model of osteoporosis, AU promoted increased cortical bone thickness, increased bone density, and tighter trabecular bone, and stimulated an increase in the expression of collagen I, osteocalcin, osteopontin, osterix, and phosphorylated Akt and Smads in bone tissue.

In a separate study examining osteoclast inhibition, C57BL/6 mice were divided into control, dexamethasone-induced osteoporosis, and aucubin-treated groups (5 or 45 mg/kg); administration lasted for 7 weeks, and 1, 2.5, and 5 µM aucubin were incubated with RANKL-induced RAW264.7 cells for 7 days to observe osteoclast differentiation. AU increased the number of trabeculae and reduced the loss of chondrocytes in OP mice; compared to OP mice, AU-treated mice exhibited decreased serum concentrations of TRAP5b, IL-1, IL-6, and ROS, and increased serum concentrations of SOD and CAT.

One study specifically used human bone marrow mesenchymal stem cells (hBMSCs) from postmenopausal osteoporosis (PMOP) patients. Aucubin, isolated from the well-known herbal medicine Eucommia, was previously shown to possess various pharmacological effects; however, its effects on hBMSCs from PMOP patients were unknown, and the aim of the research was to investigate the impact and underlying process of aucubin on cell proliferation and osteogenic differentiation in hBMSCs isolated from PMOP patients. This represents an ex vivo, cell-based experiment and does not constitute a clinical trial.

A 2025 systematic review of Eucommia ulmoides and its compounds in bone diseases reported: ninety studies met the inclusion criteria; the evidence demonstrates that Eucommia ulmoides and its bioactive compounds — most notably aucubin, geniposide, rutin, and pinoresinol diglucoside — consistently promote osteoblastogenesis and inhibit osteoclastogenesis, with effects mediated through modulation of key signaling pathways including BMP/SMAD, Wnt/β-catenin, OPG/RANKL, and MAPK/NF-κB.

4.5 Antioxidant Activity

Evidence level: Preclinical (in vitro and in vivo). Strong mechanistic consistency across multiple models.

In vitro and in vivo studies reveal that aucubin has a wide range of activities, including anti-inflammatory, antioxidant, anxiolytic and antidepressant, antidiabetic, antifibrotic, antimicrobial, anticancer, antihyperlipidemic, gastroprotective, cardioprotective, hepatoprotective, retinoprotective, neuroprotective, osteoprotective, and renoprotective activities. The antioxidant action is predominantly mediated through activation of the Nrf2/HO-1 pathway and suppression of reactive oxygen species (ROS) generation, consistent across liver, bone, brain, and reproductive tissue models.

4.6 Anticancer Activity

Evidence level: Preclinical only (cell lines and animal tumor models). No human evidence.

In a mouse breast cancer model, the study aimed to verify the anticancer effect of aucubin on breast cancer; the breast cancer model was established with mouse 4T1 cell line and BALB/c mice, aucubin was given once a day by gavage for 14 days, and the results showed that aucubin suppressed the growth of tumor in vivo by inducing tumor cell apoptosis, with a tumor suppression rate of 51.31 ± 4.07%.

Earlier work using synthetic derivatives explored the mechanisms: a novel iridoid glycoside derived from aucubin, comprising the same conjugated cyclopentenone pharmacophore as known antitumor oxylipins and prostaglandins, displayed significant antiproliferative in vitro activity towards leukemia L1210 cells. These findings are based on animal models and cell lines and cannot be extrapolated to clinical outcomes in humans.

4.7 Antidiabetic and Metabolic Effects

Evidence level: Preclinical (animal and cell models).

In vitro and in vivo studies indicate that aucubin has a wide range of activities including antidiabetic and antihyperlipidemic activity. In diabetic liver fibrosis models, aucubin, as an active ingredient isolated from Eucommia ulmoides, exists with a nutritional value in hepatoprotective effect and diabetic complications; however, whether it possesses outstanding features on improving liver injury in diabetic conditions and the underlying mechanism remained unclear at the time of study. Metabolic effects including activation of AMPK and PPARα/γ pathways point to potential insulin-sensitizing and lipid-lowering mechanisms that warrant further investigation in human trials.

4.8 Wound Healing and Antimicrobial Activity

Evidence level: Preclinical and limited traditional/observational evidence.

Plantamajoside, acteoside, aucubin, and ursolic acid are among the chemicals present in Plantago major leaves that have wound-healing properties. Aucubin's wound-healing potential is derived from its convergent anti-inflammatory, antioxidant, and antimicrobial activities. Aucubin shows promise for a variety of therapeutic and biomedical applications because of its biological activities including antifungal and antimicrobial activity.

4.9 Anxiety and Depression

Evidence level: Preclinical (animal behavioral studies).

Aucubin, an iridoid glycosidic natural compound extracted from various plants including Aucuba japonica, Veronica persica, and Eucommia ulmoides, has been investigated in vivo for its anxiolytic and related properties. Animal behavioral models have demonstrated anxiolytic and antidepressant-like effects, which have been attributed to modulation of hippocampal neuroinflammation and neurotransmitter balance, but clinical evidence is absent.

4.10 Cardiovascular and Renoprotective Effects

Evidence level: Preclinical.

Aucubin has multiple functions including cardioprotective and other protective effects identified in experimental systems. Aucubin has been reported to promote angiogenesis in a mouse hindlimb ischemia model. Renoprotective effects have been observed in cell and animal models of oxidative and inflammatory kidney injury, consistent with aucubin's broader anti-inflammatory and antioxidant mechanisms.

5. Pharmacokinetics

Although aucubin has been shown to have poor oral bioavailability in rats, aucubin is widely distributed in multiple organs including kidney, liver, heart, spleen, and lung, and there is a sex difference in the absorption of aucubin.

Although aucubin has been shown to have poor oral bioavailability in rats, aucubin is widely distributed in multiple organs including kidney, liver, heart, spleen, and lung, and there is a sex difference in the absorption of aucubin. This sex-dependent pharmacokinetic difference has been noted in rodent studies and its significance in humans is unknown. The instability of aucubin's structure, which facilitates hydrolysis to aucubigenin, is considered a factor in both its bioavailability limitations and the potential for gut-microbiome-mediated biotransformation.

Studies of the pharmacokinetics and safety of AU are increasing year by year; researchers have reviewed the sources, physicochemical properties, pharmacodynamics, pharmacokinetics, and toxicology of aucubin in order to provide a theoretical reference for its comprehensive development and utilization.

6. Dosage Forms and Reported Dosages

As of the available literature, no standardized human dosing guidelines exist for isolated aucubin. The following dosages are those reported specifically in cited studies, and are not recommendations.

Topical anti-inflammatory model: Aucubin applied topically in a TPA-induced mouse ear edema model had a maximum effect at a dose of 1 mg/ear, close to that of indomethacin at 0.5 mg/ear.
Rat chondrocyte/osteoarthritis model (in vitro): Rat chondrocytes were cultured and pretreated with aucubin at concentrations of 1, 10, 20, or 50 μM, then stimulated with or without IL-1β (10 ng/ml).
Liver ischemia-reperfusion (rat, intraperitoneal): AU was administered intraperitoneally at doses of 1, 5, and 10 mg/kg/day for 10 days.
Neurological ischemia model (gerbil, intraperitoneal): Aucubin (10 mg/kg) was administered intraperitoneally once a day for one week prior to IR induction.
Osteoporosis model (mouse, oral gavage): Mice received 5 or 45 mg/kg of aucubin for 7 weeks.
Osteoclast inhibition (in vitro): 1, 2.5, and 5 µM AU were incubated with RANKL-induced RAW264.7 cells for 7 days to observe osteoclast differentiation.
Breast cancer (mouse, oral gavage): Aucubin was given once a day by gavage for 14 days. The specific dose per kg was not reported in available search results for this study.
Traumatic brain injury (in vitro): Various concentrations of AU (50 μg/ml, 100 μg/ml, or 200 μg/ml) were added to culture medium at 0 h and 6 h after neurons were stimulated by H₂O₂ (100 μM).

7. Safety Considerations

7.1 General Toxicology and Tolerance

Tolerance of aucubin is good and no serious adverse reactions have been observed to date; aucubin is a compound with abundant potential sources and good safety. This assessment, however, is based on preclinical data and the safety profile of the aucubin-containing plant Eucommia ulmoides in traditional use; systematic human safety data for isolated, purified aucubin are limited.

In animal studies establishing dosing ranges for osteoporosis experiments, the LD₅₀ of AU was greater than 45 mg/kg in the mouse model employed, indicating a relatively wide safety margin at doses used in preclinical studies.

Aucubin is characterized as a low-toxicity compound across multiple preclinical review sources. To accelerate development and utilization of aucubin-related products, it is necessary to introduce advanced separation and formulation technologies to improve the yield and stability of aucubin products, and studies should focus on the specific pharmacological activities of aucubin to determine the structure-activity relationship so as to improve the efficacy and reduce side effects.

7.2 Pharmacokinetic Stability Concern

Aucubin is unstable and can be deglycosylated into its aglycone, aucubigenin. This chemical instability raises questions about the consistency and shelf-life of aucubin-containing products. To date, AU has only been extracted from plants; because of the unstable structure of AU, few pure products can be obtained. The hydrolysis product aucubigenin may have its own biological activities and safety profile that differ from those of intact aucubin.

7.3 Bioavailability Limitation

Aucubin has been shown to have poor oral bioavailability in rats, and there is a sex difference in the absorption of aucubin. This may influence the effective dose in humans and could limit the reliability of extrapolating rodent dose-response data to human supplementation contexts. Extensive studies on its drug delivery systems will be needed to help maximize efficacy and minimize side effects.

7.4 Drug Interactions

No formally characterized drug-drug interactions with isolated aucubin have been reported in the peer-reviewed literature identified for this article. Given its documented modulation of the NF-κB, AMPK, Nrf2/HO-1, PPARα/γ, and TLR4 pathways, and its effects on liver metabolism including hepatoprotective activity against cytochrome P450-mediated toxicity (e.g., CCl₄-induced damage), theoretical interactions with hepatically metabolized drugs or anti-inflammatory medications are plausible but uncharacterized in humans. Studies should focus on the specific pharmacological activities of aucubin to determine the structure-activity relationship so as to improve efficacy and reduce side effects.

7.5 Gaps in Human Safety Data

Further research in humans is urgently needed primarily to substantiate clinical evidence. The current absence of human clinical trials means that the safety profile, effective dose range, tolerability, and potential interactions in human populations remain to be formally characterized. Preclinical safety assessments in rodents are encouraging, but they are not sufficient to establish a complete human safety profile.

Summary of Evidence Strength

Anti-inflammatory (NF-κB / TLR4 suppression): Strong, consistent mechanistic evidence in multiple preclinical models across organ systems; no human RCTs.
Hepatoprotection: Robust preclinical evidence including multiple animal models of toxic, ischemic, and metabolic liver injury; traditional use corroborates; no human clinical trials with isolated aucubin.
Neuroprotection (ischemia, neurodegeneration, epilepsy): Multiple animal model studies with consistent findings; no human trials.
Bone metabolism (osteoporosis, fracture, OA): Convergent evidence from cell, animal, and ex vivo human-cell studies; one supporting systematic review of the parent plant. No human RCTs for isolated aucubin.
Anticancer: Early-stage, cell-line and animal tumor model evidence only; mechanism not established in humans.
Antidiabetic / metabolic: Preclinical animal and cell data; no human evidence.
Antioxidant (Nrf2/HO-1 pathway): Mechanistically well-characterized in multiple preclinical models; clinical relevance in humans unknown.
Anxiolytic / antidepressant: Animal behavioral model data only; no human evidence.

References

Health Conditions

Health conditions that Aucubin may help support.

No conditions available.

Body Systems

Body systems that Aucubin may help support.

No body systems available.